Cobra 1/NELF-B as Booster for CD8+ T Cell-Based Therapy - US12600755B2

The USPTO granted Patent US12600755B2 to The George Washington University on April 14, 2026. The patent covers methods of generating T cells comprising transgenes encoding negative elongation factor (NELF) complex subunits, specifically Cobra 1/NELF-B, integrated into the T cell genome. The disclosed methods are directed to enhancing CD8+ T cell-based therapies for treating cancer and infectious diseases.

For biotechnology and pharmaceutical companies developing T cell-based immunotherapies, gene therapies, or cell engineering platforms, this patent may affect research and development activities. Parties developing similar technologies may need to consider licensing arrangements or design-around strategies to avoid potential infringement. Academic and research institutions conducting work in this area should consult with technology transfer offices regarding potential licensing requirements.